BRAF and MEK targeted inhibitors can block the MAPK pathway, allowing the normal expression of tumor cell antigens for recognition by T cells (33); 2 The BRAFV600 mutation promotes tumor cell immune escape, and the combined application of BRAF and MEK inhibitors can be used in the early stages to regulate the body’s immune microenvironment, trigger increased expression of melanoma cell surface antigens and CD8+T cytotoxicity markers (perforin and granzyme B), thereby promoting T cell infiltration and lymphocyte proliferation (34). Here, CD8A is linked to melanoma.